论文部分内容阅读
目的探讨首发精神分裂症患儿治疗前后外周血淋巴细胞多巴胺D3受体(DRD3)基因mRNA表达水平的变化,分析DRD3基因的表达与儿童精神分裂症之间的关系。方法选择首发精神分裂症患儿(精神分裂症组)和健康儿童(健康对照组)各40例。应用RT-PCR方法测定健康对照组及精神分裂症组治疗前后外周血DRD3 mRNA的表达,采用阴性和阳性症状量表(PANSS量表)评定症状严重程度和临床疗效。采用SPSS 12.0软件,根据数据特征进行独立样本t检验、双因素方差分析及Pearson相关分析。结果精神分裂症患儿治疗前及服药后第1周DRD3 mRNA水平均高于健康对照组,差异均有统计学意义(t=7.89、3.79,Pa=0.000),第2-4周与健康对照组比较,差异无统计学意义(t=1.10、0.16、-1.13,P=0.262、0.873、0.276);精神分裂症组不同时间DRD3 mRNA表达量双因素变量分析显示各时间组间比较差异有统计学意义(F=450.63,P=0.000);治疗前PANSS评分与DRD3mRNA表达呈正相关(r=0.428,P=0.006);治疗4周后,PANSS总分减分率与服药前后DRD3 mRNA的变化无相关性(r=0.100,P=0.541)。结论首发精神分裂症患儿外周血DRD3 mRNA的相对表达量与精神分裂症存在关系,其表达量越高,症状越严重,在一定时期内DRD3 mRNA的表达变化与临床症状改善程度不同步。
Objective To investigate the expression of DRD3 gene mRNA in peripheral blood lymphocytes of children with first-episode schizophrenia before and after treatment, and to analyze the relationship between DRD3 gene expression and schizophrenia in children. Methods Forty children with first-episode schizophrenia (schizophrenia group) and healthy children (healthy control group) were enrolled in this study. The expression of DRD3 mRNA in peripheral blood of healthy control group and schizophrenia group before and after treatment was determined by RT-PCR. The severity of symptoms and clinical efficacy were evaluated by negative and positive symptom scales (PANSS). SPSS 12.0 software was used to perform independent sample t test, two-way ANOVA and Pearson correlation analysis according to the data characteristics. Results The levels of DRD3 mRNA in children with schizophrenia before treatment and after 1 week of treatment were significantly higher than those in healthy controls (t = 7.89, 3.79, Pa = 0.000) (T = 1.10,0.16, -1.13, P = 0.262,0.873,0.276). Two-factor analysis of DRD3 mRNA expression at different times in schizophrenia group showed that there were statistically significant differences among the time groups PANSS score was positively correlated with DRD3 mRNA expression before treatment (r = 0.428, P = 0.006). After 4 weeks of treatment, the total score of PANSS decreased and DRD3 mRNA before and after treatment did not change Correlation (r = 0.100, P = 0.541). Conclusions The relative expression of DRD3 mRNA in peripheral blood of first-episode schizophrenia is related to schizophrenia. The higher the expression level is, the more serious the symptoms are. The expression of DRD3 mRNA is not synchronized with the improvement of clinical symptoms in a certain period.